SCHEMBL24651346

SCHEMBL24651346

C/C=N\C(=C/C)C(=O)Nc1cc2cn[nH]c2cc1C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ TSHR P16473 1/20 0.36
▸ ROCK2 O75116 2/20 0.36
▸ ROCK1 Q13464 2/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ NPC1 O15118 4/20 0.35
▸ RAB9A P51151 4/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ POLB P06746 1/20 0.34
▸ DHODH Q02127 1/20 0.34
▸ MKNK1 Q9BUB5 3/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ AXL P30530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23022589 0.91 MAPT (0.36) MAPTL3MBTL1IRAK4TSHRROCK2
SCHEMBL19687762 0.89 MAPT (0.36) MAPTL3MBTL1IRAK4TSHRROCK2
SCHEMBL21863731 0.83 DHODH (0.38) MAPTL3MBTL1IRAK4TSHRROCK2
SCHEMBL21216701 0.82 MAPT (0.36) MAPTL3MBTL1IRAK4TSHRROCK2
SCHEMBL22176843 0.77 MAPT (0.43) MAPTL3MBTL1IRAK4TSHRROCK2
SCHEMBL20883618 0.72 L3MBTL1 (0.34) MAPTL3MBTL1ROCK2ROCK1MEN1
SCHEMBL18183739 0.71 TSHR (0.49) MAPTL3MBTL1TSHRROCK2ROCK1
SCHEMBL28087713 0.71 L3MBTL1 (0.41) MAPTL3MBTL1IRAK4ROCK2ROCK1
SCHEMBL16845679 0.70 IRAK4 (0.49) MAPTL3MBTL1IRAK4TSHRMEN1
SCHEMBL20909097 0.70 L3MBTL1 (0.35) MAPTL3MBTL1ROCK2ROCK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174508-A1 SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-06-08 — — US disclosed
US-20220249456-A1 USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174508-A1 SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS CYP11B2, CYP11B1, CYP19A1 MAPT 1069/4885L3MBTL1 4434/4885IRAK4 230/4885
US-20220249456-A1 USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES IDO2, IL33, IDO1 MAPT 1611/4885L3MBTL1 4357/4885IRAK4 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback